4Suppliers
2Customers
3Debt Items
0Related Chains

Source-Backed Evidence Depth

Quoin Pharmaceuticals, Ltd. (QNRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

19Total relationships
2Distinct source URLs
17High confidence
0.898Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Quoin Pharmaceuticals, Ltd. Suppliers

TickerNameConfidenceEvidence
SKINVISIBLE-PHARMACEUTICALS-INC SKINVISIBLE-PHARMACEUTICALS-INC 92% Under which Skinvisible granted us an exclusive royalty-bearing license relating to the production and manufacture of prescription drug products
CONTRACT-MANUFACTURER-OF-THE-DRUG-PRODUCT-FOR-CL CONTRACT-MANUFACTURER-OF-THE-DRUG-PRODUCT-FOR-CL 90% The Company is also dependent on several third party suppliers, in some cases a single source supplier including the contract manufacturer of the drug product for clinical development
CONTRACT-RESEARCH-ORGANIZATION CONTRACT-RESEARCH-ORGANIZATION 90% The Company is also dependent on several third party suppliers, in some cases a single source supplier including the contract research organization managing both of the Company’s current clinical studies
SUPPLIER-OF-THE-ACTIVE-PHARMACEUTICAL-INGREDIENT SUPPLIER-OF-THE-ACTIVE-PHARMACEUTICAL-INGREDIENT 90% The Company is also dependent on several third party suppliers, in some cases a single source supplier including the supplier of the active pharmaceutical ingredient (API)

Quoin Pharmaceuticals, Ltd. Customers

TickerNameConfidenceEvidence
EVESTIA-CLINICAL-LIMITED EVESTIA-CLINICAL-LIMITED 62% equity financings. We incurred net losses of approximately $5.0 million and negative cash flows from operations of $4.9 million for the three months ended March 31, 2026. At March 31, 2026, we had ca…
QUOIN-PHARMACEUTICALS-LTD QUOIN-PHARMACEUTICALS-LTD 62% Item 1A, “Risk Factors” of our Form 10-K. You should carefully consider the factors discussed in our Form 10-K, which could materially affect our business, financial condition or future results. The …

Quoin Pharmaceuticals, Ltd. Debt Obligations

InstrumentDescriptionConfidenceEvidence
QNRX-DEBT Debt stack $2.2M 90% Market cache reports total debt of $2.2M.
QNRX-DEBT-11999 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-12-31.
QNRX-DEBT-11998 Warrants outstanding: 16.13 90% xbrl warrant detail from xbrl 2025-10-14.

Quoin Pharmaceuticals, Ltd. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Quoin Pharmaceuticals, Ltd..

Quoin Pharmaceuticals, Ltd. Ownership

HolderNameConfidenceEvidence
QNRX-OWNER-AIGH-CAPITAL-MANAGEMENT-LLC AIGH Capital Management LLC 95% 13F/ownership overlay lists AIGH Capital Management LLC; shares held 49,323; ownership 5.88%; value $316,160; as of 2025-12-31.
QNRX-OWNER-BOOTHBAY-FUND-MANAGEMENT-LLC Boothbay Fund Management, LLC 95% 13F/ownership overlay lists Boothbay Fund Management, LLC; shares held 59,838; ownership 7.13%; value $383,561; as of 2025-12-31.
QNRX-OWNER-SUMMITTX-CAPITAL-L-P Summittx Capital, L.P. 95% 13F/ownership overlay lists Summittx Capital, L.P.; shares held 64,795; ownership 7.72%; value $415,335; as of 2025-12-31.
QNRX-OWNER-MILLENNIUM-MANAGEMENT-LLC Millennium Management Llc 95% 13F/ownership overlay lists Millennium Management Llc; shares held 74,817; ownership 8.92%; value $479,576; as of 2025-12-31.
QNRX-OWNER-RESOLUTE-CAPITAL-ASSET-PARTNERS-LLC Resolute Capital Asset Partners Llc 95% 13F/ownership overlay lists Resolute Capital Asset Partners Llc; shares held 30,000; ownership 3.58%; value $192,299; as of 2025-12-31.
QNRX-OWNER-STONEPINE-CAPITAL-MANAGEMENT-LLC Stonepine Capital Management, LLC 95% 13F/ownership overlay lists Stonepine Capital Management, LLC; shares held 78,189; ownership 9.32%; value $501,191; as of 2025-12-31.
QNRX-OWNER-ABERDEEN-GROUP-PLC Aberdeen Group plc 95% 13F/ownership overlay lists Aberdeen Group plc; shares held 75,000; ownership 8.94%; value $480,749; as of 2025-12-31.
QNRX-OWNER-WOODLINE-PARTNERS-LP Woodline Partners LP 95% 13F/ownership overlay lists Woodline Partners LP; shares held 79,582; ownership 9.49%; value $510,120; as of 2025-12-31.
QNRX-OWNER-IKARIAN-CAPITAL-LLC Ikarian Capital, LLC 95% 13F/ownership overlay lists Ikarian Capital, LLC; shares held 211,538; ownership 25.21%; value $1.4M; as of 2025-12-31.
QNRX-OWNER-ADAR1-CAPITAL-MANAGEMENT-LLC Adar1 Capital Management, LLC 95% 13F/ownership overlay lists Adar1 Capital Management, LLC ; shares held 58,230; ownership 6.94%; value $373,254; as of 2025-12-31.

Quoin Pharmaceuticals, Ltd. Extended Supply Chain Network

No secondary connectionsNo correlated companies found through shared supply chain relationships.
🔐
QNRX
Unlock QNRX Supply Chain Data
Verified relationships include:
SKINVISIBLE-PHARMACEUTICALS-INCSKINVISIBLE-PHARMACEUTICALS-INCSupplier92%
CONTRACT-MANUFACTURER-OF-THE-DRUG-PRODUCT-FOR-CLCONTRACT-MANUFACTURER-OF-…Supplier90%
EVESTIA-CLINICAL-LIMITEDEVESTIA-CLINICAL-LIMITEDCustomer62%
QUOIN-PHARMACEUTICALS-LTDQUOIN-PHARMACEUTICALS-LTDCustomer62%
+15 more relationships locked
Subscribe — View plans →